drugset / Trial / NCT00536393

Treatment of Disseminated High Grade Lymphoma

NCT00536393

Phase 2/3 Completed 100 enrolled French Innovative Leukemia Organisation
RandomizedParallel-groupOpen-labelTreatment

Summary

Interest of the use of pegylated liposomal doxorubicin (caélyx)

Timeline

Start
2000-10
Primary completion
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified

Indications